A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Alfred Chung
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Alfred Chung
Dr. Alfred Chung is a hematologist-oncologist who cares for patients with blood cancers, including leukemias, lymphomas and myelomas. He sees patients who are in the hospital for treatment, including those who need a bone marrow transplant and those receiving chemotherapy or cellular therapies to bolster the immune system.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Janssen Research & Development, LLC
- ID
- NCT06500884
- Phase
- Phase 2 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- Expecting 130 study participants
- Last Updated